Robin Zon: We have witnessed too much suffering and even death from this disease
Robin Zon,
“As a community doctor without SS expertise in our area , we have witnessed too much suffering and even death from this disease. I still remember my very first clinic patient in my IM internship 30 plus years ago who had to meet the program director Outside just to get pain medicine! This fantastic discovery and approval not only changes the life of the patients but also the lives of their families ! We are so grateful to you Dr. Frangoul -now the challenge is getting this out to the community and getting it reimbursed.”
Quoting
“Please meet Dr. Haydar Frangoul – the amazing doctor who spearheaded the new US FDA Approval of the First Gene Therapies to Treat Patients with Sickle Cell Disease.
Such a great honor to partner with such amazing colleagues to provide tomorrow’s cutting edge treatments today in our clinic SCRI, Haydar Frangoul, Precision Medicine for the win.
HUGE MILESTONE in all of MEDICINE just in time for the ASH23 meeting & huge win for patients & families with sickle cell disease the US FDA Approved the First Gene Therapies to Treat Patients with Sickle Cell Disease FDA
Sickle cell disease is a group of inherited blood disorders affecting approximately 100,000 people in the U.S. It is most common in African Americans.
Dr. Haydar Frangoul, Director of Stem Cell Transplant, Sarah Cannon Research Institute, The Children’s Hospital at Tristar Centennial spearheaded the CRISPR-Cas9 clinical trial Sarah Cannon Research Institute
Link to FDA approval here.
Link to an amazing patient story here.
Sickle cell Precision Medicine for the win.”
Source: Robin Zon/LinkedIn and Vivek Subbiah/LinkedIn
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.
Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.